MX390495B - Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica. - Google Patents
Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica.Info
- Publication number
- MX390495B MX390495B MX2018011349A MX2018011349A MX390495B MX 390495 B MX390495 B MX 390495B MX 2018011349 A MX2018011349 A MX 2018011349A MX 2018011349 A MX2018011349 A MX 2018011349A MX 390495 B MX390495 B MX 390495B
- Authority
- MX
- Mexico
- Prior art keywords
- lateral sclerosis
- amyotrophic lateral
- masitinib
- treatment
- subpopulation
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 4
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 2
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004655 masitinib Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162490 | 2016-03-25 | ||
| PCT/EP2017/057134 WO2017162884A1 (en) | 2016-03-25 | 2017-03-24 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018011349A MX2018011349A (es) | 2019-02-07 |
| MX390495B true MX390495B (es) | 2025-03-20 |
Family
ID=55637258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011349A MX390495B (es) | 2016-03-25 | 2017-03-24 | Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10092564B2 (https=) |
| EP (1) | EP3240538B1 (https=) |
| JP (2) | JP7250312B2 (https=) |
| KR (1) | KR102293847B1 (https=) |
| CN (1) | CN108883108B (https=) |
| AU (1) | AU2017236177B2 (https=) |
| BR (1) | BR112018069515A2 (https=) |
| CA (1) | CA3018635C (https=) |
| DK (1) | DK3240538T3 (https=) |
| EA (1) | EA038531B1 (https=) |
| ES (1) | ES2899929T3 (https=) |
| HU (1) | HUE057398T2 (https=) |
| IL (1) | IL261856B (https=) |
| MX (1) | MX390495B (https=) |
| NZ (1) | NZ745778A (https=) |
| PL (1) | PL3240538T3 (https=) |
| PT (1) | PT3240538T (https=) |
| SG (1) | SG11201808106YA (https=) |
| SI (1) | SI3240538T1 (https=) |
| WO (1) | WO2017162884A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| CA2889446C (en) | 2012-10-25 | 2021-05-11 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| AU2014340182B2 (en) | 2013-10-22 | 2019-05-23 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| CA3033079A1 (en) * | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| BR112019009711A2 (pt) | 2016-11-25 | 2019-08-13 | Genuv Inc | método de indução de neuro-regeneração, método de proteção de neurônios contra perda ou dano neuronal, método de prevenção ou tratamento de doença neurodegenerativa devido à perda ou dano neuronal, e método de triagem de candidatos de fármaco para o tratamento de doenças neurodegenerativas |
| MX394840B (es) * | 2017-03-28 | 2025-03-24 | Novartis Ag | Nuevos metodos para el tratamiento de la esclerosis multiple. |
| CA3065365C (en) * | 2017-05-30 | 2025-09-16 | Deciphera Pharmaceuticals, Llc | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR |
| KR102874471B1 (ko) | 2018-03-05 | 2025-10-31 | 매사추세츠 아이 앤드 이어 인퍼머리 | 콜로니 자극 인자의 표적화에 의한 녹내장 및 시신경병증 치료법 |
| KR20210071943A (ko) | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 소듐 및 α-락토스의 분말화된 제형 |
| WO2020123449A1 (en) | 2018-12-10 | 2020-06-18 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| CN112618717A (zh) * | 2019-09-24 | 2021-04-09 | 北京大学深圳研究生院 | Btk抑制剂用于治疗肌萎缩侧索硬化症的用途 |
| CN115243681B (zh) * | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| EP4132507A4 (en) | 2020-04-06 | 2024-05-15 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| WO2025113494A1 (zh) * | 2023-11-27 | 2025-06-05 | 浙江径科医药有限公司 | 多环类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (https=) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| CA2494695C (en) | 2002-08-02 | 2011-04-05 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| NZ578944A (en) | 2007-02-13 | 2011-03-31 | Ab Science | PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS |
| US8906357B2 (en) | 2010-04-20 | 2014-12-09 | Ab Science | Treatment of multiple sclerosis with masitinib |
| KR101951220B1 (ko) | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | 조합 als 치료법 |
| DK2903616T3 (da) * | 2012-10-04 | 2018-01-29 | Ab Science | Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer |
| WO2014145909A2 (en) * | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
-
2017
- 2017-03-24 MX MX2018011349A patent/MX390495B/es unknown
- 2017-03-24 PL PL17712175T patent/PL3240538T3/pl unknown
- 2017-03-24 SG SG11201808106YA patent/SG11201808106YA/en unknown
- 2017-03-24 EA EA201800499A patent/EA038531B1/ru unknown
- 2017-03-24 DK DK17712175.3T patent/DK3240538T3/da active
- 2017-03-24 EP EP17712175.3A patent/EP3240538B1/en active Active
- 2017-03-24 AU AU2017236177A patent/AU2017236177B2/en active Active
- 2017-03-24 PT PT177121753T patent/PT3240538T/pt unknown
- 2017-03-24 US US15/545,800 patent/US10092564B2/en active Active
- 2017-03-24 SI SI201730997T patent/SI3240538T1/sl unknown
- 2017-03-24 CA CA3018635A patent/CA3018635C/en active Active
- 2017-03-24 CN CN201780019760.9A patent/CN108883108B/zh active Active
- 2017-03-24 HU HUE17712175A patent/HUE057398T2/hu unknown
- 2017-03-24 KR KR1020187026871A patent/KR102293847B1/ko active Active
- 2017-03-24 WO PCT/EP2017/057134 patent/WO2017162884A1/en not_active Ceased
- 2017-03-24 NZ NZ745778A patent/NZ745778A/en not_active IP Right Cessation
- 2017-03-24 BR BR112018069515A patent/BR112018069515A2/pt not_active Application Discontinuation
- 2017-03-24 ES ES17712175T patent/ES2899929T3/es active Active
- 2017-03-24 JP JP2018549902A patent/JP7250312B2/ja active Active
-
2018
- 2018-09-20 IL IL261856A patent/IL261856B/en unknown
-
2021
- 2021-12-16 JP JP2021204244A patent/JP2022037132A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201800499A1 (ru) | 2019-03-29 |
| JP2022037132A (ja) | 2022-03-08 |
| EP3240538B1 (en) | 2021-09-29 |
| BR112018069515A2 (pt) | 2019-04-16 |
| JP7250312B2 (ja) | 2023-04-03 |
| AU2017236177A1 (en) | 2018-09-20 |
| PL3240538T3 (pl) | 2022-01-31 |
| SG11201808106YA (en) | 2018-10-30 |
| JP2019515884A (ja) | 2019-06-13 |
| WO2017162884A1 (en) | 2017-09-28 |
| IL261856B (en) | 2022-04-01 |
| DK3240538T3 (da) | 2021-12-06 |
| IL261856A (en) | 2018-10-31 |
| NZ745778A (en) | 2022-07-01 |
| PT3240538T (pt) | 2021-12-07 |
| AU2017236177B2 (en) | 2022-03-31 |
| CN108883108A (zh) | 2018-11-23 |
| US10092564B2 (en) | 2018-10-09 |
| CN108883108B (zh) | 2021-08-06 |
| SI3240538T1 (sl) | 2022-02-28 |
| MX2018011349A (es) | 2019-02-07 |
| ES2899929T3 (es) | 2022-03-15 |
| EP3240538A1 (en) | 2017-11-08 |
| KR102293847B1 (ko) | 2021-08-26 |
| US20180117037A1 (en) | 2018-05-03 |
| CA3018635C (en) | 2023-09-26 |
| CA3018635A1 (en) | 2017-09-28 |
| KR20180125966A (ko) | 2018-11-26 |
| HUE057398T2 (hu) | 2022-05-28 |
| EA038531B1 (ru) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390495B (es) | Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica. | |
| JOP20200011B1 (ar) | مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| MX2018015625A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| UA118149C2 (uk) | Інгібітор jak | |
| JO3474B1 (ar) | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 | |
| BR112018071585A2 (pt) | formulações de um inibidor de lsd1 | |
| CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
| MX384792B (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX383887B (es) | Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich. | |
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| PL417066A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| SG10201804026WA (en) | Inhibitors of influenza viruses replication | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| UY35687A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| MX390051B (es) | Antagonistas de ep4. | |
| JOP20190053A1 (ar) | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط | |
| JOP20200100A1 (ar) | مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| JOP20220160A1 (ar) | مركبات فعّالة نحو مستقبلات نووية | |
| EP4477265A3 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists |